Daniel Chu Joins 23andMe as Chief Product Officer
September 19 2022 - 5:45AM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer
genetics and research company, today appointed Daniel Chu as Chief
Product Officer.
Prior to joining 23andMe, Chu served as Chief Product Officer
for Waymo, where he launched the world’s first commercial fully
autonomous ride-hailing service. He oversaw the product management,
program management, user experience design and research, industrial
design, product data science and strategy teams for the company.
Before Waymo, Chu led the Google Maps platform product team, which
included the Google Maps API, one of the most popular APIs
available.
“Dan is a collaborative, data-driven leader that can build
consumer products and services at scale. He has proven he can
navigate highly technical and regulated environments for consumer
facing products. We are excited to welcome Dan as we build out our
genomic health platform,” said Anne Wojcicki, Chief Executive
Officer and Co-Founder of 23andMe.
“I’m excited to be joining a founder-led, mission-driven company
that’s focused on using data to revolutionize health, wellness and
research,” said Chu. “23andMe has helped bring genetics into the
mainstream and I look forward to joining the company as it embarks
on transforming healthcare to deliver a more personalized
experience. 23andMe has a passionate team building impactful
products and services that truly have the potential to help people
live longer, healthier lives.”
Chu holds Bachelor of Science (BS) and Bachelor of Arts (BA)
degrees from Stanford University, a Master of Business
Administration (MBA) degree from Harvard Business School, and a
Master of Public Administration (MPA) degree from Harvard Kennedy
School.
About 23andMe23andMe is a genetics-led consumer
healthcare and therapeutics company empowering a healthier future.
For more information, please visit www.23andMe.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding the future performance of
23andMe’s businesses in consumer genetics and therapeutics and the
growth and potential of its proprietary research platform. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding
23andMe’s strategy, financial position, funding for continued
operations, cash reserves, projected costs, plans, and objectives
of management, are forward-looking statements. The words
"believes," "anticipates," "estimates," "plans," "expects,"
"intends," "may," "could," "should," "potential," "likely,"
"projects," “predicts,” "continue," "will," “schedule,” and "would"
or, in each case, their negative or other variations or comparable
terminology, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on 23andMe’s current expectations and projections about
future events and various assumptions. 23andMe cannot guarantee
that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K and in its subsequent reports on Forms 10-Q and
8-K. The statements made herein are made as of the date of this
press release and, except as may be required by law, 23andMe
undertakes no obligation to update them, whether as a result of new
information, developments, or otherwise.
Contacts: Investor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/515f0e84-3766-467c-91ec-e93d42b4411a
23andMe (NASDAQ:ME)
Historical Stock Chart
From Apr 2024 to May 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
From May 2023 to May 2024